Multinational phase 2 study of pembrolizumab for previously treated MSI-H/dMMR advanced endometrial cancer

Treatment options for endometrial cancer after failure of first-line therapy are limited. The multinational phase 2 KEYNOTE-158 study evaluated the efficacy and safety of the anti-PD-1 antibody pembrolizumab in patients with previously treated advanced endometrial cancer with tumors that had high levels of microsatellite instability/mismatch repair deficiency. The study found robust and durable antitumor activity robust and durable antitumor activity and encouraging survival outcomes with manageable toxicity of pembrolizumab.